2. Search Result
Search Result
Results for "

lipid+synthesis

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

12

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113596
    Acetyl Coenzyme A trisodium
    4 Publications Verification

    Acetyl-CoA trisodium

    		 Oxidative Phosphorylation Endogenous Metabolite Autophagy Metabolic Disease
    Acetyl-coenzyme A (Acetyl-CoA) trisodium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trisodium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trisodium is also a key precursor of lipid synthesis .
    Acetyl Coenzyme A trisodium
  • HY-N2468
    Xylobiose

    1,4-β-D-Xylobiose; 1,4-D-Xylobiose

    		 TNF Receptor Claudin HSP Metabolic Disease Inflammation/Immunology
    Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
    Xylobiose
  • HY-114293A
    Acetyl coenzyme A trilithium

    Acetyl-CoA trilithium

    		 Oxidative Phosphorylation Endogenous Metabolite Autophagy Cardiovascular Disease Metabolic Disease
    Acetyl-coenzyme A (Acetyl-CoA) trilithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trilithium regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trilithium is also a key precursor of lipid synthesis .
    Acetyl coenzyme A trilithium
  • HY-30216A
    Leucic acid

    α-Hydroxyisocaproic acid

    		 Drug Metabolite Hydroxycarboxylic Acid Receptor (HCAR) AMPK ERK Metabolic Disease Inflammation/Immunology
    Leucic acid (α-Hydroxyisocaproic acid) is an orally active end-product of the microbial metabolism of leucine. Leucic acid can bind to HCAR2, alters AMPK and ERK1/2 phosphorylation status, suppresses lipid synthesis, promotes catabolism, reduces adiposity, enhances lean mass and exercise capacity. Leucic acid suppresses pro-inflammatory cytokine secretion, inflammation-related gene mRNA expression. Leucic acid decreases basal protein synthesis, attenuates myotube atrophy. Leucic acid can be used for the research of obesity .
    Leucic acid
  • HY-114293
    Acetyl coenzyme A

    Acetyl-CoA

    		 Oxidative Phosphorylation Endogenous Metabolite Autophagy Cardiovascular Disease Metabolic Disease
    Acetyl-coenzyme A (Acetyl-CoA) is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A is also a key precursor of lipid synthesis .
    Acetyl coenzyme A
  • HY-N10319
    Artepillin C

    		Epigenetic Reader Domain Necroptosis TRP Channel Metabolic Disease Inflammation/Immunology Cancer
    Artepillin C is an orally active CREB/CRTC2 inhibitor and TRPA1 covalent agonist (EC50=1.8 μM). Artepillin C inhibits CREB/CRTC2-mediated gene transcription and downregulates BMAL1 expression to regulate glucose and lipid metabolism. Artepillin C can also activate TRPA1 channels to induce spicy taste signals. Artepillin C can inhibit tumor cell proliferation, induce necroptosis, improve insulin resistance and inhibit liver lipid synthesis. Artepillin C can be used in the study of metabolic syndrome, tumor prevention and treatment, and inflammation .
    Artepillin C
  • HY-160912
    ELOVL6-IN-5

    		ELOVL Metabolic Disease
    ELOVL6-IN-5 is an orally active and selective elongase enzyme of long-chain fatty acid family 6 (ELOVL6) inhibitor with IC50 values of 85 nM and 38 nM for human and mouse ELOVL6, respectively. ELOVL6-IN-5 shows >60-fold selectivity over other ELOVL family enzymes (ELOVL1, 2, 3, 5) and no effect on other lipid synthesis enzymes like ACC1, ACC2. ELOVL6-IN-5 reduces hepatic fatty acid composition ratio of C18 to C16 in diet-induced obesity (DIO) and KKAy mice. ELOVL6 inhibition by ELOVL6-IN-5 does not improve insulin resistance. ELOVL6-IN-5 can be used for the research of metabolic disease .
    ELOVL6-IN-5
  • HY-109056
    Elsulfavirine
    2 Publications Verification

    R-1206

    		 Drug Intermediate HIV Reverse Transcriptase Carbonic Anhydrase Infection Cancer
    Elsulfavirine (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer .
    Elsulfavirine
  • HY-113596A
    Acetyl coenzyme A lithium
    4 Publications Verification

    Acetyl-CoA lithium

    		 Oxidative Phosphorylation Endogenous Metabolite Autophagy Cardiovascular Disease Metabolic Disease
    Acetyl-coenzyme A (Acetyl-CoA) lithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A lithium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A lithium is also a key precursor of lipid synthesis .
    Acetyl coenzyme A lithium
  • HY-114293S
    Acetyl coenzyme A-13C2 lithium

    Acetyl-CoA-13C2 lithium

    		 Isotope-Labeled Compounds Endogenous Metabolite Autophagy Oxidative Phosphorylation Metabolic Disease
    Acetyl coenzyme A- 13C2 lithium is the 13C-labeled Acetyl coenzyme A (HY-114293). Acetyl-coenzyme A (Acetyl-CoA) is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A is also a key precursor of lipid synthesis .
    Acetyl coenzyme A-13C2 lithium
  • HY-110028
    Leelamine hydrochloride

    		Cannabinoid Receptor Fatty Acid Synthase (FASN) Androgen Receptor Endocrinology Cancer
    Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees . Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis [2,3].
    Leelamine hydrochloride
  • HY-P2989
    Pyruvate carboxylase

    		Endogenous Metabolite Metabolic Disease Cancer
    Pyruvate carboxylase is a key mitochondrial anaplerotic enzyme that catalyzes the conversion of pyruvate to oxaloacetate. Pyruvate carboxylase not only maintains tricarboxylic acid cycle activity and redox homeostasis, but also drives hepatic gluconeogenesis and fatty acid synthesis. The activity of Pyruvate carboxylase is upregulated in insulin-resistant states, exacerbating hepatic glucose production. Pyruvate carboxylase also shows significantly enhanced expression in early-stage non-small cell lung cancer (NSCLC). Pyruvate carboxylase promotes tumor proliferation by supporting nucleotide and lipid synthesis, and its functional deficiency cannot be compensated by glutaminolysis. Pyruvate carboxylase can be used in the research of prediabetes type 2 and NSCLC .
    Pyruvate carboxylase
  • HY-114293S5
    Acetyl coenzyme A-d3

    Acetyl-CoA-d3

    		 Isotope-Labeled Compounds Oxidative Phosphorylation Endogenous Metabolite Autophagy Cardiovascular Disease Metabolic Disease
    Acetyl coenzyme A-d3 (Acetyl-CoA-d3) is the deuterium labeled Acetyl coenzyme A (HY-114293). Acetyl-coenzyme A (Acetyl-CoA) is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A is also a key precursor of lipid synthesis .
    Acetyl coenzyme A-d3
  • HY-B2007
    Fluazifop-P-butyl

    		Environmental Pollutants Acetyl-CoA Carboxylase Herbicide Metabolic Disease Inflammation/Immunology
    Fluazifop-P-butyl is an orally active herbicide and ACCase inhibitor. Fluazifop-P-butyl blocks the formation of malonyl-CoA, disrupts lipid synthesis in sensitive plants, and exhibits concentration-dependent phytotoxicity to non-target maize seedlings. Fluazifop-P-butyl induces oxidative stress in male Wistar rats, impairs their liver and kidney functions, and disrupts testicular function .
    Fluazifop-P-butyl
  • HY-170027
    LW1564

    		HIF/HIF Prolyl-Hydroxylase AMPK Cancer
    LW1564 is an inhibitor for HIF-1α with an IC50 of 1.2 µM in HepG2. LW1564 inhibits mitochondrial respiration, reduces ATP production, stimulates HIF-1α degradation, and inhibits proliferation of various cancer cells with GI50 of 0.4-4.6 μM. LW1564 activates AMPK signaling pathway and inhibits lipid synthesis. LW1564 exhibits antitumor in HepG2 xenograft mouse model .
    LW1564
  • HY-N10612
    Petasin

    		AMPK PPAR TRP Channel Mitochondrial Metabolism Metabolic Disease Cancer
    Petasin inhibits adipogenesis in cell 3T3-F442A with an IC50 of 0.95 μM. Petasin inhibits the expression of lipid synthesis factors ACC1, FAS and SCD1 by inhibiting transcription factors PPARγ and C/EBPα, as well as targeting TRPA1 and TRPV1 channels . Petasin inhibits mitochondrial complex I, thereby inhibiting tumor growth and metastasis. Petasin activates AMPK signaling pathway, participating in regulation of glucose and lipid metabolism. Petasin is orally active .
    Petasin
  • HY-N10319R
    Artepillin C (Standard)

    		Reference Standards TRP Channel Necroptosis Epigenetic Reader Domain Metabolic Disease Inflammation/Immunology Cancer
    Artepillin C (Standard) is the analytical standard of Artepillin C (HY-N10319). This product is intended for research and analytical applications. Artepillin C is an orally active CREB/CRTC2 inhibitor and TRPA1 covalent agonist (EC50=1.8 μM). Artepillin C inhibits CREB/CRTC2-mediated gene transcription and downregulates BMAL1 expression to regulate glucose and lipid metabolism. Artepillin C can also activate TRPA1 channels to induce spicy taste signals. Artepillin C can inhibit tumor cell proliferation, induce apoptosis, improve insulin resistance and inhibit liver lipid synthesis. Artepillin C can be used in the study of metabolic syndrome, tumor prevention and treatment, and inflammation .
    Artepillin C (Standard)
  • HY-N8495
    4'-Hydroxyflavanone

    		Others Metabolic Disease
    4'-Hydroxyflavanone is an inhibitor of SREBP maturation and lipid synthesis. 4'-Hydroxyflavanone is a synthetic analogue of flavanone, has potential for hepatic steatosis and dyslipidemia research .
    4'-Hydroxyflavanone
  • HY-19428A
    Ranbezolid hydrochloride

    RBx-7644

    		 Antibiotic Bacterial Infection Cardiovascular Disease
    Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC50 of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria .
    Ranbezolid hydrochloride
  • HY-19428
    Ranbezolid

    RBx7644 free base

    		 Antibiotic Bacterial Infection Cardiovascular Disease
    Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC50 of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria .
    Ranbezolid
  • HY-N2468R
    Xylobiose (Standard)

    1,4-β-D-Xylobiose (Standard); 1,4-D-Xylobiose (Standard)

    		 Reference Standards TNF Receptor Claudin HSP Metabolic Disease Inflammation/Immunology
    Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
    Xylobiose (Standard)
  • HY-U00332
    Hydrocarbon chain derivative 1

    6,6'-Oxybis[2,2-dimethyl-1-hexanol]

    		 Drug Derivative Metabolic Disease
    Hydrocarbon chain derivative 1 is an active compound, with inhibitory activities against lipid synthesis.
    Hydrocarbon chain derivative 1
  • HY-105900
    Ro 22-0654

    		Others Metabolic Disease
    Ro 22-0654 is a potent lipid synthesis inhibitor. Ro 22-0654 inhibits hepatic fatty acid synthesis and has antiobesity effects .
    Ro 22-0654
  • HY-N8495R
    4'-Hydroxyflavanone (Standard)

    		Fatty Acid Synthase (FASN) Reference Standards Metabolic Disease
    4'-Hydroxyflavanone (Standard) is the analytical standard of 4'-Hydroxyflavanone. This product is intended for research and analytical applications. 4'-Hydroxyflavanone is an inhibitor of SREBP maturation and lipid synthesis. 4'-Hydroxyflavanone is a synthetic analogue of flavanone, has potential for hepatic steatosis and dyslipidemia research[1].
    4'-Hydroxyflavanone (Standard)
  • HY-E70262
    Acetoyl-CoA triammonium

    		Oxidative Phosphorylation Endogenous Metabolite Metabolic Disease
    Acetoyl-CoA (triammonium) is a triammonium derivative of Acetoyl-CoA (HY-114293), Acetyl-CoA is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A is also a key precursor of lipid synthesis .
    Acetoyl-CoA triammonium
  • HY-162703
    Lipid-lowering agent-2

    		AMPK Metabolic Disease
    Lipid-lowering agent-2 (Compound 14d) is an orally active lipid-lowering agent with an EC50 of 0.06 μM. Lipid-lowering agent-2 inhibits the lipid synthesis, activates the AMPK signaling pathway, and exhibits anti-obesity effect. Lipid-lowering agent-2 inhibits food intake, improves the glucose metabolism, and reduces the body weight and adipose tissue in high-fat diet (HFD)-induced obese mice .
    Lipid-lowering agent-2
  • HY-118843
    Lombazole

    		Potassium Channel Infection
    Lombazole is an antimicrobial compound with activity that inhibits cell membrane synthesis. Lombazole had little effect on K+ permeability in S. aureus. Lombazole inhibited only de novo synthesis of cell enclosure in S. aureus, and this effect occurred before growth was affected. The main effect of lombazole was through inhibition of lipid synthesis. Lombazole may have an effect on key steps in lipid biosynthesis, as inferred from the lack of changes in lipid patterns after treatment. Lombazole also inhibited the sterol C-14 demethylation step in Candida albicans .
    Lombazole
  • HY-B2007R
    Fluazifop-P-butyl (Standard)

    		Reference Standards Acetyl-CoA Carboxylase Metabolic Disease
    Fluazifop-P-butyl (Standard) is the analytical standard of Fluazifop-P-butyl (HY-B2007). This product is intended for research and analytical applications. Fluazifop-P-butyl is an orally active herbicide and ACCase inhibitor. Fluazifop-P-butyl blocks the formation of malonyl-CoA, disrupts lipid synthesis in sensitive plants, and exhibits concentration-dependent phytotoxicity to non-target maize seedlings. Fluazifop-P-butyl induces oxidative stress in male Wistar rats, impairs their liver and kidney functions, and disrupts testicular function .
    Fluazifop-P-butyl (Standard)
  • HY-113947
    Metamifop

    		Herbicide Acetyl-CoA Carboxylase Others
    Metamifop is a post-emergence lipid synthesis inhibitor herbicide, with an IC50 of 41.1 nM against the carboxyltransferase (CT) domain of chloroplast acetyl-CoA carboxylase (ACCase) in barnyard grass (Echinochloa crus-galli). Metamifop inhibits the activity of the CT domain, thereby blocking fatty acid biosynthesis .
    Metamifop
  • HY-P2992A
    Inorganic Pyrophosphatase, Bacillus stearothermophilus

    		Biochemical Assay Reagents Metabolic Disease
    Inorganic Pyrophosphatase, Bacillus stearothermophilus (EC 3.6.1.1) catalyzes the conversion of one molecule of pyrophosphate to two phosphate ions. The functionality of Inorganic Pyrophosphatase, Bacillus stearothermophilus (EC 3.6.1.1) plays a critical role in lipid metabolism (including lipid synthesis and degradation), calcium absorption and bone formation, and DNA synthesis,as well as other biochemical transformations.
    Inorganic Pyrophosphatase, Bacillus stearothermophilus
  • HY-109056A
    Elsulfavirine sodium

    R-1206 sodium

    		 HIV Drug Intermediate Reverse Transcriptase Carbonic Anhydrase Infection Cancer
    Elsulfavirine sodium (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine sodium also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine sodium and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine sodium is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine sodium exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine sodium is used in studies related to HIV-1 infection and liver cancer .
    Elsulfavirine sodium
  • HY-109056R
    Elsulfavirine (Standard)

    R-1206 (Standard)

    		 Reference Standards Drug Intermediate HIV Reverse Transcriptase Carbonic Anhydrase Infection Cancer
    Elsulfavirine (Standard) is the analytical standard of Elsulfavirine (HY-109056). This product is intended for research and analytical applications. Elsulfavirine (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer .
    Elsulfavirine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: